Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 51, 1701-1707, March 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taki, T.
Right arrow Articles by Handa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taki, T.
Right arrow Articles by Handa, S.

Had-1, a Uridine 5'-Diphosphogalactose Transport-defective Mutant of Mouse Mammary Tumor Cell FM3A: Composition of Glycolipids, Cell Growth Inhibition by Lactosylceramide, and Loss of Tumorigenicity1

Takao Taki2, Kiyoshi Ogura, Chiaki Rokukawa, Takahiko Hara, Masao Kawakita, Tamao Endo, Akira Kobata and Shizuo Handa

Department of Biochemistry, Faculty of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113 [T. T., K. O., C. R., S. H.]; Department of Pure and Applied Science, College of Arts and Science, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153 [T. H., M. K.]; and Department of Biochemistry, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108 [E. T., A. K.], Japan

Glycolipid compositions of mouse mammary tumor cell FM3A and its Newcastle disease virus-resistant mutant cell, Had-1, which was also characterized as a defective mutant of UDP-galactose transport to Golgi apparatus, have been studied. The major neutral glycolipid in FM3A was Galß1-4Glcß1-1Cer (LacCer) (95%) and the rest was Glcß1-1Cer. The concentration of neutral glycolipids in Had-1 was only about one-fifth of that in FM3A. GlcB1-1Cer in Had-1 accounted for 79% of neutral glycolipids and the rest was LacCer, the content of which was decreased to 4% of that in FM3A. Ganglioside patterns of the two cell lines were similar, although gangliosides with N-glycolylneuraminic acid were increased in Had-1 cells compared with that in FM3A cells. The presence of NeuAc{alpha}2-3-Galß1-4GlcNAcß1-3Galß1-4Glcß1-1Cer, NeuAc{alpha}2-3Galß1-4GlcNAcß1-3Galß1-4GlcNAcß1-3Galß1-4Glcß1-2Cer, GM3, and GD3 was demonstrated by thin-layer chromatography immunostaining. 125I-Labeled Newcastle disease virus bound only poorly to gangliosides extracted from either FM3A or Had-1 cells on a high performance thin-layer chromatography plate. The effects of glycolipids on the growth of the two cell lines were also studied. Had-1 cells were more sensitive to glycolipids added exogenously than FM3A cells. Addition of GM3 had a stimulative effect on cell growth of Had-1. LacCer, Galß1-3GalNAcß1-4Galß1-4Glcß4-1Cer, and Glcß1-1Cer inhibited the growth of Had-1 cells. LacCer was the most potent inhibitor. LacCer immobilized on the culture plate also inhibited the growth of Had-1 cells. The inhibitory effect was recovered completely overcome by transferring the cells to LacCer-free medium. Had-1 cells were not tumorigenic in C3H/He mice, and furthermore the tumorigenic activity of FM3A cells was suppressed by the prior administration of Had-1 cells.

1 This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan and from Nagase Science and Technology Foundation.

2 To whom requests for reprints should be addressed.

Received 8/13/90. Accepted 1/ 3/91.




This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
H. Sprong, S. Degroote, T. Nilsson, M. Kawakita, N. Ishida, P. van der Sluijs, and G. van Meer
Association of the Golgi UDP-Galactose Transporter with UDP-Galactose:Ceramide Galactosyltransferase Allows UDP-Galactose Import in the Endoplasmic Reticulum
Mol. Biol. Cell, August 1, 2003; 14(8): 3482 - 3493.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Kumamoto, Y. Goto, K. Sekikawa, S. Takenoshita, N. Ishida, M. Kawakita, and R. Kannagi
Increased Expression of UDP-Galactose Transporter Messenger RNA in Human Colon Cancer Tissues and Its Implication in Synthesis of Thomsen-Friedenreich Antigen and Sialyl Lewis A/X Determinants
Cancer Res., June 1, 2001; 61(11): 4620 - 4627.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Miura, A. Aspberg, I. M. Ethell, K. Hagihara, R. L. Schnaar, E. Ruoslahti, and Y. Yamaguchi
The Proteoglycan Lectin Domain Binds Sulfated Cell Surface Glycolipids and Promotes Cell Adhesion
J. Biol. Chem., April 16, 1999; 274(16): 11431 - 11438.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Aoki, N. Ishida, and M. Kawakita
Substrate Recognition by UDP-galactose and CMP-sialic Acid Transporters. DIFFERENT SETS OF TRANSMEMBRANE HELICES ARE UTILIZED FOR THE SPECIFIC RECOGNITION OF UDP-GALACTOSE AND CMP-SIALIC ACID
J. Biol. Chem., June 8, 2001; 276(24): 21555 - 21561.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1991 by the American Association for Cancer Research.